Mankind Pharma on Wednesday recorded a profit growth of 10.2 per cent during the first quarter of FY25 at Rs 536.49 crore. This is in comparison to Rs 486.87 crore posted during the first quarter of the previous financial year. It recorded revenue from operations at Rs 2,893.42 crore, up 12.2 per cent as against Rs 2,578.62 crore during the corresponding quarter of FY24. The company EBITDA stood at Rs 681.8 crore, up 4 per cent on-year. 

The company posted domestic revenue at Rs 2,634 crore, up 9% YoY and exports at Rs 259 crore, up 62 per cent YoY. Domestic secondary sales grew by 10.5 per cent vs 8.7 per cent IPM growth (1.2x to IPM) supported by: a) strong volume growth of 1.9 per cent vs 0.4 per cent for IPM; and b) out-performance in chronic therapies (1.3x to IPM Chronic). It said that growth was partially impacted by a delayed season in anti-infectives, and certain product withdrawals in Q1FY24. Prescriber penetration, it said, increased to 83.2 per cent in Q1FY25.

Also Read

The Consumer Healthcare Business recorded recovery in revenue with 32 per cent QoQ increase in Q1FY25 supported by faster growth in modern trade, e-commerce and q-commerce channels.

Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said, “We witnessed a steady revenue growth of 12.2 per cent YoY with continued outperformance of 1.2x to IPM driven by a strong recovery in volume with adjusted EBITDA margins of 25.2 per cent. We are now the second largest pharma company by volume with an increase in market share of 20 bps YoY to 6.1 per cent.”